Monoclonal Antibodies                                    Technology, Technology Offers, Production, Projects, Market, Applications, Company Profiles                                            Primary Information Services                                                   Home. Ordering Information. Contact

Information at a Glance

  • Monoclonal antibodies(mAbs) are just like antibodies except they are artificially produced from the clones of a single cell.
  • Monoclonal antibodies are made by multiple, identical copies (i.e. clones) of a cell called a hybridoma.
  • Monoclonal antibodies are produced by fusing single antibody-forming cells to tumor cells grown in culture. The resulting cell is called a hybridoma.
  • Monoclonal antibodies are created with cell fusion technology and cell culture technology .
  • Once a monoclonal antibody is made, it can be used as a specific probe to track down and purify the specific protein that induced its formation.
  • Monoclonal antibodies can be used to classify strains of a single pathogen, e.g. Neisseria gonorrhoeae can be typed using monoclonal antibodies.
  • Monoclonal antibodies are widely used as diagnostic and research reagents. Their introduction into human therapy has been much slower.
  • Monoclonal antibodies (MABs or MOABs) work on cancer cells in the same way natural antibodies work, by identifying and binding to the target cells.
  • The market for therapeutic monoclonal antibodies (mAbs) is one of the most dynamic sectors within the pharmaceutical industry.
  • The current global clinical antibody pipeline, which comprises 132 products in development and is dominated by humanized (42%) and fully human (28%)mAbs, is poised to deliver as many as 16 new products between 2004 and 2008.
  • As a result of growth in existing markets for mAb therapeutics,and the opening of new ones, the global market is projected to increase to US $16.7 billion in 2008.
  • The mAbs market is expected to almost triple in value over the next six years from $10.3 billion in 2004 to $30.3 billion. Oncology products will continue to dominate the market. However, sales of arthritis, immune and inflammatory disorders (AIID) products are forecast to grow strongly and account for 40.1% of the market by 2010.
  • Chimeric mAbs were the undisputed leaders,with 43% growth and US $3.8 billion in sales, followed by humanized
    mAbs with more than US $1.4 billion in sales and growth of 29%.
  • The development focus of the industry is moving away from murine and chimeric antibodies, to humanized and, in particular, fully human technologies. A wave of fully human products are expected to launch from 2007 onwards, accounting for 12 of the 20 launches between 2007 and 2010.
  • Roche and Genentech dominate the mAbs market, with a combined market share of 44.9% in 2004, although this is forecast to slip to 35.7% in 2010.
  • Next generation antibodies are forecast to drive the market towards the $30 billion mark by 2011 due to a high level of innovation in early-stage discovery and several potential nichebusters set to launch in the next 5 years.
  • Applications of Monoclonal Antibodies include: Identification of Cell Surface Markers , Detection Assays , Purification Techniques , Gene Identification , Disease Therapy , Use in Applied Chemistry

Entrepreneur who want the information can E-Mail us to informer@eth.net, primaryinfo@gmail.com

Primary Information Services
 21 Murugappan St, SwamyNagar Ext2, 
Ullagaram, Chennai - 600091, India.
 Phone: 91 44 22421080 
Email :
informer@eth.net, primaryinfo@gmail.com
Mobile numbers:9940043898, 9444008898  Fax : 91 44 22423753